10 Nugent Road
Surrey Research Park
GU2 7AF
+44 (0)1483 302560
+44 (0)1483 534864
Michael Hunt
They are a leading, clinical-stage stem cell business. They have used their unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional drug treatments. Their lead therapeutic candidate is our ReN001 stem cell therapy for the treatment of patients left disabled by the effects of a stroke. This treatment is currently in clinical development. They are also developing stem cell therapies for other conditions such as critical limb ischaemia, a serious and common side effect of diabetes, and blindness-causing diseases of the retina.
| Description | Report Date | Published |
|---|---|---|
| Annual Report 2013 | 31-03-2013 | 09-08-2013 |
| Annual Report 2012 | 31-03-2012 | 09-07-2012 |
| Annual Report 2011 | 31-03-2011 | 22-07-2011 |
| Annual Report 2010 | 31-03-2010 | 30-07-2010 |
| Annual Report 2009 | 31-03-2009 | 23-07-2009 |
| Annual Report 2008 | 31-03-2008 | 08-07-2008 |
| Annual Report 2007 | 31-03-2007 | 06-07-2007 |
| Annual Report 2006 | 31-03-2006 | 14-08-2006 |
| Description | Report Date | Published |
|---|---|---|
| Interim Report 2012 | 30-09-2012 | 04-12-2012 |
| Interim Report 2010 | 30-09-2010 | 13-12-2010 |
| Interim Report 2009 | 30-09-2009 | 26-11-2009 |
| Interim Report 2008 | 30-09-2008 | 28-11-2008 |
| Interim Report 2007 | 30-09-2007 | 03-12-2007 |
| Interim Report 2006 | 30-09-2006 | 06-12-2006 |
| Interim Report 2005 | 30-09-2005 | 30-11-2005 |
| Description |
|---|
| Webcast |
| Events Calendar |
| Home |
| Results Index |
| Press Releases |
| Contacts |
| Type | Dividend | Payment Date |
|---|---|---|
| Nil | 0.0000 | 01-01-1970 |